20/20 Biolabs, Inc.
AIDX
$1.46
$0.096.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.71% | 31.74% | 30.29% | 30.48% | 23.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.71% | 31.74% | 30.29% | 30.48% | 23.03% |
| Cost of Revenue | 3.48% | 6.54% | 14.56% | 15.52% | 5.86% |
| Gross Profit | 67.78% | 175.32% | 113.79% | 125.99% | 229.95% |
| SG&A Expenses | -29.77% | -29.68% | -0.80% | 1.05% | -5.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.48% | -22.35% | -1.05% | -2.02% | -4.78% |
| Operating Income | 41.16% | 36.83% | 10.09% | 10.07% | 11.01% |
| Income Before Tax | 32.65% | 34.78% | 7.45% | 8.40% | 13.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.65% | 34.78% | 7.45% | 8.40% | 13.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.65% | 34.78% | 7.45% | 8.40% | 13.14% |
| EBIT | 41.16% | 36.83% | 10.09% | 10.07% | 11.01% |
| EBITDA | 41.24% | 36.97% | 9.76% | 9.94% | 10.87% |
| EPS Basic | 34.76% | 35.44% | 8.39% | 9.19% | 13.78% |
| Normalized Basic EPS | 34.58% | 35.76% | 8.72% | 9.48% | 11.12% |
| EPS Diluted | 34.78% | 35.57% | 8.18% | 9.00% | 13.70% |
| Normalized Diluted EPS | 34.58% | 35.76% | 8.72% | 9.48% | 11.12% |
| Average Basic Shares Outstanding | 2.70% | 1.16% | 1.01% | 0.84% | 0.66% |
| Average Diluted Shares Outstanding | 2.70% | 1.16% | 1.01% | 0.84% | 0.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |